Navigation Links
PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy
Date:1/19/2010

rnalLink');" target='_blank' href="http://www.mda.org/">www.mda.org) or Parent Project Muscular Dystrophy (www.parentprojectmd.org).

ABOUT ATALUREN (PTC124®)

Ataluren is the first investigational new drug designed to restore the production of a functioning protein in patients with genetic disorders due to a nonsense mutation.  A nonsense mutation is an alteration in the genetic code that prematurely halts the synthesis of an essential protein, such as dystrophin in the case of nmDBMD.  Ataluren is currently being investigated for use in patients with nonsense mutation Duchenne and Becker muscular dystrophy (nmDBMD), nonsense mutation cystic fibrosis (nmCF) and nonsense mutation hemophilia A and B (nmHA/nmHB).  Ataluren has been granted orphan drug status for the treatment of nmDBMD and nmCF by the U.S. Food and Drug Administration (FDA) and the European Commission.  The FDA has also granted ataluren Subpart E and Fast Track designation for expedited development, evaluation, and marketing.  The development of ataluren has been supported by the FDA Office of Orphan Products Development, the Muscular Dystrophy Association, Parent Project Muscular Dystrophy, the Cystic Fibrosis Foundation Therapeutics Inc. (the nonprofit affiliate of the Cystic Fibrosis Foundation), and the National Center for Research Resources.

COLLABORATION WITH GENZYME

PTC Therapeutics has an exclusive collaboration with Genzyme Corporation for the development and commercialization of ataluren.  PTC Therapeutics will commercialize ataluren in the United States and Canada, while G
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. NASDAQ Trading for Oxygen Biotherapeutics, Inc. Shares to Begin January 15, 2010
2. Echo Therapeutics Announces Major Milestone: The Completion of Product Development Work of its Revolutionary, Patented Prelude(TM) SkinPrep System
3. Advanced Cardiac Therapeutics Completes $5 Million Financing
4. Cell Therapeutics, Inc. (CTI) to Present at the 28th Annual JP Morgan Healthcare Conference
5. Oxygen Biotherapeutics, Inc. Announces Approval for NASDAQ Listing
6. Anesiva Announces Merger With Arcion Therapeutics Will Not be Completed
7. Cell Therapeutics, Inc. Adopts Shareholder Rights Plan
8. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
9. PTC Therapeutics Closes $50 Million Financing
10. Fate Therapeutics iPSC Technology Awarded Top Industry Honors for Small Molecule and Protein Reprogramming Breakthroughs
11. European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 20, 2014  The acceptance of ... 2014 AAGL Global Congress demonstrates continued interest in ... to provide bowel control. One of the abstracts, presented ... and Division Chief of Urogynecology and Reconstructive Pelvic ... an Award for Best Written Abstract on Urogynecology/Pelvic ...
(Date:11/21/2014)... , Nov. 20, 2014   Coqui RadioPharmaceuticals Corp. ... first U.S. commercial producer of Molybdenum-99 (Mo-99), is proud ... INVAP to design its Medical Isotope Production ... Mo-99 is the parent isotope of Technetium-99, which is ... In 2012, Congress passed legislation making it a national ...
(Date:11/21/2014)... , Nov. 21, 2014  Lexicon Pharmaceuticals, Inc. (Nasdaq: ... its previously announced underwritten public offering of $50,000,000 of ... shelf registration statement. The offering will consist of 49,751,244 ... of $1.005 per share.  Lexicon has also granted the ... additional shares of common stock.  All of the shares ...
Breaking Medicine Technology:LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 2LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 3Coqui RadioPharmaceuticals Inks Deal With INVAP 2Lexicon Announces Pricing Of Common Stock Offering 2Lexicon Announces Pricing Of Common Stock Offering 3
... FDA approvals for prostate cancer treatment medications from ... of men with advanced prostate cancer were prolonged ... & Johnson. The drug, which could reach the market in ... the potential to change clinical practice by providing a new ...
... The Food and Drug Administration (FDA) is warning there ... thigh bone fracture in people who take drugs known ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) ... type of fracture has been predominantly reported in patients ...
Cached Medicine Technology:Robotic Prostatectomy Expert Dr. David Samadi, MD Discusses Prostate Cancer Treatment Drug Abiraterone 2
(Date:11/23/2014)... (PRWEB) November 23, 2014 Locks-Magnetic.com, a ... emergency doors. Moreover, all the new products are available ... The marketing manager is proud of the new emergency ... reset automatically. And customers can choose from several colors. ... Buying high quality emergency door release is not as ...
(Date:11/23/2014)... 2014 To show thanks to new and ... of white evening dresses for weddings. Customers who ... , iFitDress.com is a distinguished dress manufacturer, and it is ... worldwide customers for a very long time. The CEO of ... customer will be able to buy not only a beautiful ...
(Date:11/23/2014)... NY (PRWEB) November 23, 2014 More ... past month in a federal litigation involving Byetta lawsuits ... diabetes medications, Bernstein Liebhard LLP reports. , A ... claims over a class of Type 2 diabetes medications ... in the U.S. District Court, Southern District of California, ...
(Date:11/23/2014)... 23, 2014 Asher Milgrom, is ... & Wellness was recently featured on International ... president and CEO of American Medical Aesthetics & Wellness, ... received a full scholarship to attend an M.D./Ph.D program ... at the University of Chicago, where his field of ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 The FDA ... in Common, **FDAnews On-Demand Webinar**, Dec. 11, 2014 ? ... , The FDA’s focus on promotional activities is no ... , Now they're looking at websites, Twitter, journal articles, ... calendar for Thursday, Dec. 11, for On-Demand access to ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 3Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 4Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 3Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 3Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 5
... standard part of testicular cancer care isnt used in ... condition, researchers at the University of Michigan Comprehensive Cancer ... one indicator of the presence of cancer cells, are ... with testis cancer, including diagnosis, prognostication and surveillance for ...
... 26-Week Study, WILMINGTON, Del., March 17 ... combination asthma therapy,SYMBICORT(R) (budesonide/formoterol fumarate dihydrate), in treating,persistent ... The study examined the,safety of SYMBICORT in children ... children previously treated with inhaled corticosteroid,either alone or ...
... Reduces Surgery Time, AUDUBON, Pa., March ... held spinal implant manufacturer in the world, ... Spacer System. The,new system significantly reduces the ... by offering an unprecedented array of,interoperative options. ...
... Kim Watson to Expand Global Partnerships for Clean Pesticide and Animal ... ... March 17 TyraTech (AIM:,TYR), a pioneer of safer, effective and ... markets, announced today,the appointment of Kim Watson as Senior Director Business ...
... March 17 Conseco, Inc. (NYSE:,CNO) today announced that ... to nominate two of its representatives to Conseco,s board ... strategic,alternatives and has engaged the investment banking firm of ... Prieur said, "We share with Steel Partners, as well ...
... SPRINGVILLE, Calif., March 17 Tropical Traditions,announced today that ... line. It is believed to be the first product ... made from the water inside of coconuts is a,cottage ... Water from,the inside of coconuts is highly valued due ...
Cached Medicine News:Health News:Testicular cancer gauge often not used 2Health News:Study Analyzed Long-Term SYMBICORT(R) Use in Children With Persistent Asthma 2Health News:Study Analyzed Long-Term SYMBICORT(R) Use in Children With Persistent Asthma 3Health News:Study Analyzed Long-Term SYMBICORT(R) Use in Children With Persistent Asthma 4Health News:Globus Medical Launches NIKO(TM) Corpectomy Spacer System 2Health News:TyraTech Adds New Sr. Director Business Development 2Health News:TyraTech Adds New Sr. Director Business Development 3Health News:Tropical Traditions Announces New Organic Raw Coconut Water Vinegar 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: